stockrow
Friday 6 November 2026
Export MRKR’s income statement to Excel — free account
MARKER THERAPEUTICS, INC.
MRKR Healthcare Biotechnology
MARKER THERAPEUTICS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 46.2% from fiscal 2024.
- Revenue
- −51.0%
- EPS
- +69.0%
- Free cash flow
- −97.8%
Quarter to June 2026, against a year earlier
0.92
0.02
+2.22%
Follow MRKR
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
3.18 | 6.43 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(5.45) | (12.01) | — | — | |
P/B ratio |
0.81 | 1.36 | — | — | |
Price to Tangible BV |
0.81 | 1.36 | — | — | |
EV/Sales |
(0.49) | 2.11 | — | — | |
EV/EBITDA |
0.14 | 0.00 | — | — | |
EV/Operating CF |
0.16 | (0.62) | — | — | |
EV/FCF |
0.09 | (0.31) | — | — | |
Quick Ratio |
6.16 | 8.10 | 4.68 | 5.60 | |
Current Ratio |
6.50 | 8.39 | 4.79 | 6.03 | |
Net Debt/EBITDA |
8.87 | 25.30 | 3.59 | 4.24 | |
Debt/Assets |
0.00% | 0.00% | 5.74% | 5.52% | |
Debt/Equity |
0.00 | 0.00 | 0.07 | 0.07 | |
Asset Turnover |
0.29 | 0.17 | 0.00 | 0.00 | |
Operating CF/Net income |
1.37 | 1.12 | 0.44 | 2.04 | |
Research and Development Expense of Revenue |
190.27% | 194.01% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
83.04% | 76.72% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2.70% | 10.07% | 0.00% | 0.00% | |
Graham Net Nets |
1.23 | 0.74 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(138.20%) | (60.25%) | — | — | |
Free Cash Flow Yield |
(180.76%) | (105.89%) | — | — | |
Revenue per Share |
0.07 | 0.07 | 0.00 | 0.00 | |
Operating CF per Share |
(0.16) | (0.12) | (0.07) | (0.19) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.16) | (0.12) | (0.07) | (0.19) | |
Cash per Share |
1.13 | 1.11 | 0.81 | 0.62 | |
Shareholders Equity per Share |
1.10 | 1.10 | 0.71 | 0.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.10 | 1.10 | 0.71 | 0.63 | |
Free Cash Flow |
(2.74) | (1.90) | (1.40) | (3.72) | |
Working Capital |
18.39 | 16.80 | 13.80 | 12.17 | |
Net Current Asset Value |
18.39 | 16.80 | 13.80 | 12.17 | |
EV/EBIT |
0.14 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
1.20 | 1.86 | 1.92 | 1.65 | |
Average Payables |
2.11 | 1.53 | 2.00 | 1.65 | |
Average Assets |
16.32 | 20.55 | 17.21 | 14.68 | |
Average Common Equity |
12.92 | 17.68 | 14.14 | 11.33 |
Columns are period end dates · fundamentals updated 25 Oct 2026